Viking Therapeutics Inc. (1VT)
Summary
1VT Chart
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.18, denoting a +1.64% move from the preceding trading day.
Viking Therapeutics: Market Betting On Big Upside Through 2030
Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. VKTX targets a 5–10% market share, leveraging global expansion and late-stage development to compete with incumbents Lilly and Novo Nordisk. Nothing is over just yet. Phase 3 for VK2735 Oral is set for late 2026, with initial commercial ramp expected in 2028 and potential $1.3B sales by 2030. A hockey stick inflection could pan out.
Viking Therapeutics Inc. (1VT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Viking Therapeutics Inc. ever had a stock split?
Viking Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Lian CEO | XFRA Exchange | US92686J1060 ISIN |
| US Country | 45 Employees | - Last Dividend | - Last Split | 29 Apr 2015 IPO Date |
Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for metabolic and endocrine disorders. Established in 2012 and based in San Diego, California, Viking Therapeutics embarks on fulfilling the unmet needs within this domain by advancing a diverse portfolio of novel therapeutic candidates. Their approach leverages deep insight into disease mechanisms, aiming at delivering significant improvements over existing therapies.
Products and Services
-
VK2809:
An orally available, selective agonist of the thyroid hormone receptor beta (TRβ), primarily focused on treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Currently in Phase IIb clinical trials, VK2809 demonstrates Viking Therapeutics' commitment to addressing serious liver conditions through innovative therapeutic mechanisms.
-
VK5211:
A novel, orally available non-steroidal selective androgen receptor modulator (SARM) aimed at improving recovery in patients undergoing non-elective hip fracture surgery. Presently in Phase II clinical trials, VK5211 is designed to provide anabolic improvements of both muscle and bone, potentially representing a significant advance in post-operative care for this patient population.
-
VK0612:
Targeting the treatment of type 2 diabetes, VK0612 is an oral drug candidate ready for Phase IIb trials. By focusing on a crucial aspect of metabolic disease management, VK0612 underscores Viking's broader strategy in addressing complex metabolic disorders via cutting-edge pharmacological solutions.
-
VK2735:
This novel compound acts as a dual agonist of the glucagon-like peptide, currently in a Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) clinical trial. VK2735's development signifies Viking Therapeutics' foray into innovative treatments that could potentially offer new options for managing metabolic diseases through unique mechanisms of action.
-
VK0214:
An orally available, selective agonist of the TRß tailored for addressing symptoms and progression of X-linked adrenoleukodystrophy. Through its clinical development, VK0214 epitomizes Viking's dedication to exploring therapeutic avenues for rare and underserved endocrine disorders, providing hope for patients and families affected by these challenging conditions.
